Official Title
Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations
Brief Summary

In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.

Status
Unknown status
Conditions
COVID-19
Interventions

Drug: Deferoxamine

Intravenous infusion of Deferoxamine

Eligibility Criteria

Inclusion Criteria:

Clinical diagnosis of COVID-19 Disease,

Exclusion Criteria:

Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,

Eligibility Gender
All
Eligibility Age
Minimum: 3 Years ~ Maximum: 99 Years
Countries
Iran, Islamic Republic of
Locations

Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Kermanshah, Iran, Islamic Republic of

Investigator: Yadollah Shakiba, MD, PhD

Contacts

Alireza Ghaffarieh, MD
+1-608-698-7334
alirezaghaffariyeh@hotmail.com

Yadollah Shakiba, MD, PhD
yshakiba@gmail.com

Investigators

Sponsors / Collaborators
Kermanshah University of Medical Sciences
NCT Number
NCT04333550
Keywords
COVID-19, Deferoxamine
MeSH Terms
COVID-19
Deferoxamine